Biodesix Inc. (BDSX)
NASDAQ: BDSXHealthcareDiagnostics & ResearchUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
BDSX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $278.76M
- EPS (TTM)
- -$3.10
- Dividend yield
- None
- 52-week range
- 5.26 – 31.97
- Day range
- 26.07 – 27.78
- Volume / Avg
- 57.53K / 101.54K
- Beta
- —
- Shares outstanding
- 10.55M
- Next earnings
- Nov 2, 2026
52-week range
BDSX stock today
Shares of Biodesix (BDSX) finished lower on Oct 7 at $26.42, a drop of 5.51% or $1.54 per share, versus the S&P 500's 0.22% decline. Shares are 17.4% below their 52-week high of $31.97, set on Sep 28, 2026 and 402.3% above the 52-week low of $5.26, in the middle of the past year's range. BDSX is up 288.5% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 261.9%.
Biodesix has posted a net loss over the last twelve months (EPS of -$3.10), so its P/E ratio is not meaningful. Biodesix's next earnings report is expected on Nov 2, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Biodesix
Company profileBiodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- CEO
- Mr. Scott Hutton
- Headquarters
- Louisville, CO
- Employees
- 334
- IPO year
- 2020
- Website
- biodesix.com
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$37.33+41.29%
- Strong buy 0
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 2, 2026
- EPS estimate
- $-0.74
BDSX news
All BDSX news- Beat the Market Like Zacks: Thermo Fisher, Cricut, Shopify in FocusNasdaqICE, FAST, DGX, TMO
- Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive TestsNasdaqBDSX, TMO, BIO, VCYT
- Biodesix Reveals Two Developing MRD Solution Collaborations With Bio-Rad And Thermo FisherNasdaqBDSX, BIO, TMO
- MDLN Gets FDA Warning for Quality Lapses in Angiographic SyringesNasdaqGMED, PACB, BDSX, MDLN
Biodesix peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| XGNExagen Inc. | 8.30 | +1.34% | $201.07M | vs BDSX |
| BNRBurning Rock Biotech Limited ADR | 15.18 | -5.77% | $160.09M | vs BDSX |
| MYGNMyriad Genetics Inc. | 4.28 | 0.00% | $409.38M | vs BDSX |
| QUCYQuantum Cyber N.V. | 1.43 | +10.85% | $120.22M | vs BDSX |
| FLGTFulgent Genetics Inc. | 20.57 | -0.05% | $565.99M | vs BDSX |
| CSTLCastle Biosciences Inc. | 33.00 | -1.08% | $1.01B | vs BDSX |
| OPKOPKO Health Inc. | 1.39 | -4.79% | $1.04B | vs BDSX |
| FRNMFreenome Inc. | 16.03 | -2.02% | $1.72B | vs BDSX |
Indexes, lists and sector
Appears in lists
Biodesix stock FAQ
What is Biodesix's stock price today?
BDSX last traded at $26.42 as of Oct 7, 4:00 PM EDT, down 5.51% on the day. Prices are delayed at least 15 minutes.
Does Biodesix pay a dividend?
No. Biodesix does not currently pay a regular cash dividend.
When is Biodesix's next earnings date?
Biodesix is expected to report earnings on Monday, November 2, 2026. Analysts expect EPS of $-0.74.
Who is Biodesix's CEO?
Mr. Scott Hutton is the chief executive officer of Biodesix Inc., which has about 334 employees.
Has BDSX ever split its stock?
Yes. The most recent BDSX stock split was a 1-for-20 split on Sep 15, 2025.
What is the BDSX 52-week high?
The 52-week high for BDSX is $31.97 and the 52-week low is $5.26. The stock is currently 17.4% below its high.